Eczema Free Forever™ Eczema Free Forever™

Ustekinumab shows promise for reducing psoriasis-associated cardiovascular comorbidity

Initial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018.
Dermatology Times – Dermatology

Drug for refractory psoriatic arthritis shows promise in clinical trial

In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided…
Eczema / Psoriasis News From Medical News Today